Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7259   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004032-21
    Sponsor's Protocol Code Number:ARGX-113-2004
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-06-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-004032-21
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
    Sperimentazione multicentrica, di fase 3, randomizzata, in doppio cieco, controllata con placebo, per valutare l’efficacia e la sicurezza di efgartigimod (ARGX-113) PH20 per via sottocutanea in pazienti adulti con trombocitopenia immune primaria
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 study to evaluate the efficacy and safety of efgartigimod PH20 Subcutaneous in adult patients with primary immune thrombocytopenia
    Studio di fase 3 per valutare l’efficacia e la sicurezza di efgartigimod PH20 per via sottocutanea in pazienti adulti con trombocitopenia immune primaria.
    A.3.2Name or abbreviated title of the trial where available
    ADVANCE SC
    ADVANCE SC
    A.4.1Sponsor's protocol code numberARGX-113-2004
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04687072
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorARGENX BV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportargenx BV
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationargenx BV
    B.5.2Functional name of contact pointRegulatory
    B.5.3 Address:
    B.5.3.1Street AddressIndustriepark Zwijnaarde 7
    B.5.3.2Town/ cityZwijnaarde
    B.5.3.3Post codeB-9052
    B.5.3.4CountryBelgium
    B.5.4Telephone number003293103400
    B.5.6E-mailregulatory@argenx.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/19/2230
    D.3 Description of the IMP
    D.3.1Product nameefgartigimod PH20 SC
    D.3.2Product code [ARGX-113]
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNefgartigimod alfa
    D.3.9.1CAS number 1821402-21-4
    D.3.9.2Current sponsor codeARGX-113
    D.3.9.4EV Substance CodeSUB198780
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number180
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection/infusion
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary immune thrombocytopenia (ITP)
    Trombocitopenia immune primaria
    E.1.1.1Medical condition in easily understood language
    Disorder that can lead to easy or excessive bruising and bleeding due to low levels of the cells that help blood clot
    Disturbo che può comportare una facile o eccessiva comparsa di ecchimosi e sanguinamento dovuti a bassi livelli delle cellule che aiutano la coagulazione sanguigna
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.1
    E.1.2Level LLT
    E.1.2Classification code 10036735
    E.1.2Term Primary thrombocytopenia
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of efgartigimod PH20 SC compared to placebo PH20 SC in achieving a sustained platelet count response in patients with chronic primary ITP, with a sustained platelet count response defined as platelet counts of > and =50×10^9/L for at least 4 of the 6 visits between week 19 and week 24 of the trial.
    Valutare l’efficacia di efgartigimod PH20 SC rispetto a placebo PH20 SC nell’ottenimento di una risposta duratura in termini di conta piastrinica in pazienti con ITP primaria cronica. La risposta duratura in termini di conta piastrinica è definita come conte piastriniche > e =50×10^9/l in almeno 4 delle 6 visite tra la settimana 19 e la settimana 24 della sperimentazione
    E.2.2Secondary objectives of the trial
    • To evaluate the efficacy of efgartigimod PH20 SC compared to placebo PH20 SC in overall platelet count response
    • To evaluate the incidence and severity of bleeding events while receiving treatment with efgartigimod PH20 SC compared to placebo PH20 SC
    •To evaluate the safety and tolerability of efgartigimod PH20 SC administered qw or every other week (q2w) compared to placebo PH20 SC
    • To evaluate the use of rescue treatment and changes in concurrent ITP therapy while receiving treatment with efgartigimod PH20 SC compared to placebo PH20 SC
    • To evaluate the effects of efgartigimod PH20 SC treatment on qualityof-life (QoL) measures and patient-reported outcomes (PRO) compared to placebo PH20 SC
    • To assess the immunogenicity of efgartigimod and rHuPH20
    • To assess the pharmacokinetics (PK) of efgartigimod PH20 SC
    • To assess the pharmacodynamic (PD) effects of efgartigimod PH20 SC
    • Valutare l’efficacia di efgartigimod PH20 SC rispetto al placebo PH20 SC sulla risposta complessiva in termini di conta piastrinica
    • Valutare l’incidenza e la gravità degli eventi di sanguinamento durante il trattamento con efgartigimod PH20 SC rispetto al placebo PH20 SC
    • Valutare la sicurezza e la tollerabilità di efgartigimod PH20 SC somministrato una volta alla settimana o ogni due settimane rispetto al placebo PH20 SC
    • Valutare l’uso del trattamento di salvataggio e le modifiche alla terapia concomitante per l’ITP durante il trattamento con efgartigimod PH20 SC rispetto al placebo PH20 SC
    • Valutare gli effetti del trattamento con efgartigimod PH20 SC sulle misurazioni della qualità della vita (QdV) e sugli esiti riferiti dai pazienti (PRO, patient-reported outcomes) rispetto al placebo PH20 SC
    • Valutare l’immunogenicità di efgartigimod e rHuPH20
    • Valutare la farmacocinetica (PK) di efgartigimod PH20 SC
    • Valutare gli effetti farmacodinamici (PD) di efgartigimod PH20 SC
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits)
    2. Male or female, aged > and =18 years at the time the informed consent form (ICF) is signed
    3. Confirmed diagnosis of primary ITP made at least 3 months before randomization and based on the American Society of Hematology Criteria, and no known etiology for thrombocytopenia
    4. Diagnosis supported by a response to a prior ITP therapy (other than TPO-RAs), in the opinion of the investigator
    5. Mean platelet count of <30×10^9/L from at least 3 documented, qualifying counts within the 3 preceding months where at least 2 of the qualifying counts must be taken during the screening period: 1 platelet count collected during the screening period and the predose platelet count on the day of randomization (visit 1). If the third count is not
    available from the 3 preceding months, this third platelet count can be obtained during the screening period.
    6. A documented history of a platelet count of <30×10^9/L before screening
    7. At the start of the trial, the participant either takes concurrent ITP treatment(s) and has received at least 1 prior therapy for ITP in the past, or the participant does not take treatment for ITP (see note) but has received at least 2 prior treatments for ITP. Participants receiving permitted concurrent ITP treatment(s) at baseline must have been
    stable in dose and frequency for at least 4 weeks before randomization. Permitted concurrent ITP medications include corticosteroids, danazol, vinca alkaloids, oral immunosuppressants, dapsone, fostamatinib, and/or oral TPO-RAs.
    Note: Participants not receiving concurrent ITP therapy are also eligible for the trial if they have not received prior ITP therapy for at least 4 weeks before baseline, and 6 months in case of prior ITP therapy with an anti-CD20 therapy (eg, rituximab).
    8. Women of childbearing potential:
    • As defined in Woman of Childbearing Potential in the protocol, women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before trial medication can be administered
    • Must be on a stable regimen for at least 1 month of a highly effective or acceptable method of contraception (see Female Contraception in the protocol) during the trial and for 90 days after the last administration of IMP
    9. Non-sterilized male participants who are sexually active with a female partner of childbearing potential must use an acceptable method of contraception, ie, a condom (see Male Contraception) from signing the ICF through the last administration of the IMP. Male participants are also not allowed to donate sperm during this time.
    1. Capacità di comprendere i requisiti della sperimentazione e di fornire il consenso informato scritto (incluso il consenso all’uso e alla divulgazione delle informazioni sanitarie correlate alla ricerca), disponibilità e capacità di ottemperare alle procedure del protocollo di sperimentazione (inclusa la presenza alle necessarie visite della sperimentazione)
    2. Sesso maschile o femminile, età > e =18 anni al momento della firma del modulo di consenso informato (ICF, informed consent form)
    3. Diagnosi confermata di ITP primaria effettuata almeno 3 mesi prima della randomizzazione e basata sui criteri della American Society of Hematology, e assenza di eziologia nota per la trombocitopenia
    4. Diagnosi supportata da una risposta a una precedente terapia per l’ITP (diversa dai TPO-RA), a giudizio dello sperimentatore
    5. Conta piastrinica media <30×109/L: almeno 3 conteggi documentati qualificanti entro i 3 mesi precedenti, in cui almeno 2 delle conte qualificanti devono essere state effettuate durante il periodo di screening: 1 conta piastrinica effettuata durante il periodo di screening e la conta piastrinica pre-dose il giorno della randomizzazione (visita 1). Se non è disponibile nei 3 mesi precedenti, la terza conta può essere eseguita durante il periodo di screening.
    6. Una conta piastrinica documentata nell’anamnesi <30×109/L prima dello screening
    7. All’inizio della sperimentazione, il/la partecipante assume uno o più trattamenti concomitanti per la ITP e ha ricevuto almeno 1 precedente terapia per la ITP in passato, oppure il/la partecipante non assume un trattamento per la ITP (vedere la nota) ma ha ricevuto almeno 2 trattamenti precedenti per la ITP. Nei partecipanti che ricevono uno o più trattamenti concomitanti permessi per la ITP al basale dose e frequenza devono essere rimasti stabili da almeno 4 settimane prima della randomizzazione.
    I farmaci concomitanti permessi per la ITP includono corticosteroidi, danazolo, alcaloidi della vinca, immunosoppressori orali, dapsone, fostamatinib e/o TPO-RA orali.
    Nota: anche i partecipanti che non ricevono una terapia concomitante per la ITP sono idonei alla sperimentazione purché non abbiano ricevuto una precedente terapia per la ITP da almeno 4 settimane prima del basale, e da 6 mesi nel caso di una precedente terapia per la ITP con un anti-CD20 (per es. rituximab).
    8. Donne in età fertile:
    • Come definito in Donne in età fertile, prima di poter ricevere il farmaco in sperimentazione le donne in età fertile devono avere un test di gravidanza sierico negativo allo screening e un test di gravidanza urinario negativo al basale
    • Devono utilizzare stabilmente da almeno 1 mese un metodo contraccettivo molto efficace o accettabile (vedere Metodi contraccettivi femminili molto efficaci), durante la sperimentazione e per 90 giorni dopo l’ultima somministrazione del medicinale sperimentale (IMP, investigational medicinal product).
    9. I partecipanti di sesso maschile non sterilizzati e sessualmente attivi con una partner di sesso femminile in età fertile devono usare una contraccezione accettabile, ad es. un profilattico (vedere Contraccezione maschile) dalla firma dell’ICF fino all’ultima somministrazione dell’IMP. Ai partecipanti di sesso maschile non è inoltre consentito donare liquido seminale in tale periodo.
    E.4Principal exclusion criteria
    1. Secondary ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune thrombocytopenia, thrombocytopenia associated with myeloid dysplasia, or hematopoietic stem cell transplant 2. Use of anticoagulants (eg, vitamin K antagonists, direct oral anticoagulants) within 4 weeks prior to randomization 3. Use of any transfusions within 4 weeks prior to randomization
    4. Use of Ig (IV, SC, or intramuscular route) or plasmapheresis (PLEX) within 4 weeks prior to randomization 5. Use of romiplostim within 4 weeks prior to randomization 6. Undergone splenectomy less than 4 weeks prior to randomization 7. Use of an investigational product within 3 months or 5 half-lives (whichever is longer) before the first dose of the IMP 8. Use of any monoclonal antibody or Fc fusion proteins, other than those previously indicated, within 6 months before the first dose of the IMP (eg, anti-CD20) 9. At the screening visit, clinically significant laboratory abnormalities as follows:• Hemoglobin < and =9 g/dL- OR –• International normalized ratio >1.5 or activated partial thromboplastin time >1.5×upper limit of normal - OR – • total IgG level <6 g/L 10. History of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for > and =3 years before the first administration of IMP. Participants with the following cancer can be included at any time: a. Adequately treated basal cell or squamous cell skin cancer b. Carcinoma in situ of the cervix c. Carcinoma in situ of the breast or d. Incidental histological finding of prostate cancer (TNM stage T1a or T1b) 11. Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160 mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments 12. History of any major thrombotic or embolic event (eg, myocardial infarction, stroke, deep venous thrombosis, or pulmonary embolism) within 12 months prior to randomization 13. History of coagulopathy or hereditary thrombocytopenia or a family history of thrombocytopenia 14. Clinical evidence of other significant serious diseases, have had a recent major surgery, or who have any other condition in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk 15. Positive serum test at screening for an active viral infection with any of the following conditions: a. Hepatitis B virus (HBV) that is indicative of an acute or chronic infection (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf) b. Hepatitis C virus (HCV) based on HCV-antibody assay (unless associated with a negative HCV RNA test) c. Human immunodeficiency virus (HIV) based on test results that are associated with an acquired immunodeficiency syndrome (AIDS)- defining condition or a CD4 count <200 cells/mm3 16. Known hypersensitivity reaction to efgartigimod, rHuPH20, or 1 of its excipients 17. Previously participated in a clinical trial with efgartigimod and have received at least 1 administration of the IMP 18. Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of the IMP 19. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening. Please refer to the protocol for the full list.
    1. ITP/trombocitopenia secondaria associata a un’altra patologia, per esempio linfoma, leucemia linfocitica cronica, infezione virale, epatite, trombocitopenia indotta o alloimmune, trombocitopenia associata a displasia mieloide o trapianto di cellule staminali ematopoietiche 2. Uso di anticoagulanti (per es. antagonisti della vitamina K, anticoagulanti orali diretti) nelle 4 settimane precedenti la randomizzazione 3. Uso di trasfusioni nelle 4 settimane precedenti la randomizzazione 4. Uso di Ig (per via EV, SC o intramuscolare) o plasmaferesi (PLEX) nelle 4 settimane precedenti la randomizzazione 5. Uso di romiplostim nelle 4 settimane precedenti la randomizzazione 6. Intervento di splenectomia meno di 4 settimane prima della randomizzazione 7. Uso di un prodotto sperimentale nel periodo pari a 3 mesi o 5 emivite (il più lungo tra i due) prima della prima somministrazione dell’IMP 8. Uso di un qualunque anticorpo monoclonale o proteine di fusione Fc, diverse da quelle precedentemente indicate, nei 6 mesi precedenti la prima somministrazione dell’IMP (per es. anti-CD20) 9. Alla visita di screening, le seguenti anomalie di laboratorio clinicamente significative: • Emoglobina < e =9 g/dL - OPPURE - • Rapporto internazionale normalizzato >1,5 o tempo di tromboplastina parziale attivata >1,5 volte il limite superiore della norma - OPPURE - • Livello delle IgG totali <6 g/L 10. Anamnesi positiva per neoplasia, se non ritenuta curata con un trattamento adeguato senza segni di recidiva da > e =3 anni prima della prima somministrazione dell’IMP. In qualunque momento è possibile includere partecipanti con le seguenti forme cancerose: a. Cancro cutaneo basocellulare o squamocellulare adeguatamente trattato b. Carcinoma in situ della cervice c. Carcinoma in situ della mammella o d. Reperto istologico accidentale di cancro della prostata (stadio TNM T1a o T1b)
    11. Ipertensione non controllata, definita come pressione arteriosa ripetutamente elevata oltre i 160 mmHg (sistolica) e/o i 100 mmHg (diastolica) nonostante trattamenti appropriati 12. Evento trombotico o embolico maggiore all’anamnesi (per es. infarto del miocardio, ictus, trombosi venosa profonda o embolia polmonare) nei 12 mesi precedenti la randomizzazione 13. Coagulopatia o trombocitopenia ereditaria all’anamnesi o familiarità per trombocitopenia
    14. Evidenza clinica di altre malattie serie significative, intervento chirurgico maggiore recente o qualunque altra condizione che, a giudizio dello sperimentatore, potrebbe confondere i risultati della sperimentazione o porre eccessivamente a rischio il/la partecipante 15. Test sierologico positivo allo screening per infezione virale attiva con una qualunque delle seguenti condizioni: a. Virus dell’epatite B (HBV) indicativo di un’infezione acuta o cronica (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf) b. Virus dell’epatite C (HCV) sulla base del test degli anticorpi anti-HCV (salvo se associato ad un test HCV RNA negativo) c. Virus dell’immunodeficienza umana (HIV) sulla base dei risultati del test che vengono associati a una condizione che definisce la sindrome dell’immunodeficienza acquisita (AIDS) o a una conta dei CD4 <200 cellule/mm3 16. Reazione di ipersensibilità nota a efgartigimod, rHuPH20 o a uno dei suoi eccipienti 17. Precedente partecipazione a una sperimentazione clinica con efgartigimod con almeno 1 somministrazione dell’IMP ricevuta 18. Soggetti di sesso femminile in gravidanza o che allattano, o che intendono iniziare una gravidanza durante la sperimentazione o nei 90 giorni successivi all’ultima somministrazione dell’IMP 19. Infezione batterica, virale o fungina attiva o cronica, clinicamente significativa e non controllata, allo screening. Si prega di far riferimento al protocollo per la lista completa.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients with chronic ITP with a sustained platelet count response defined as achieving platelet counts of > and =50×10^9/L for at least 4 of the 6 visits between week 19 and week 24 of the trial
    Quota di pazienti con ITP cronica con una risposta duratura in termini di conta piastrinica definita come l’ottenimento di conte piastriniche > e =50×10^9/l per almeno 4 delle 6 visite tra la settimana 19 e la settimana 24 della sperimentazione
    E.5.1.1Timepoint(s) of evaluation of this end point
    Up to 5 weeks (between week 19 –24)
    Fino a 5 settimane (tra le settimane 19 -24)
    E.5.2Secondary end point(s)
    1. Extent of disease control defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of > and = 50×10^9/L in the chronic ITP population
    2. Proportion of patients in the overall population (chronic and persistent ITP) with a sustained platelet count response defined as achieving platelet counts of > and =50×10^9/L for at least 4 of the 6 visits between week 19 and week 24
    3. Proportion of patients in the overall population achieving platelet counts of > and =50×10^9/L for at least 6 of the 8 visits between week 17 and 24 of the trial
    4. Proportion of patients in the overall population with overall platelet response defined as achieving a platelet count of > and =50×10^9/L on at least 4 occasions at any time during the 24-week treatment period
    5. Extent of disease control defined as the number of cumulative weeks until week 12 with platelet counts of > and =50×10^9/L in the overall population
    6. Proportion of patients in the overall population with overall platelet response defined as achieving a platelet count of > and =50×10^9/L on at least 4 occasions at any time until week 12
    7. Mean change from baseline in platelet count at each visit in the overall population
    8. Time to response defined as the time to achieve 2 consecutive platelet counts of > and =50×10^9/L in the overall population
    9. The number of cumulative weeks over the planned 24-week treatment period with platelet counts of > and =30×10^9/L and > and =20×10^9/L above baseline in the overall population
    10. In patients with baseline platelet count of <15×10^9/L, the number of cumulative weeks over the planned 24-week treatment period with platelet counts of > and =30×10^9/L and > and =20×10^9/L above baseline in the overall population
    11. Incidence and severity of the World Health Organization (WHO)- classified bleeding events in the overall population
    12. Incidence and severity of AEs, AEs of special interest (AESIs), and SAEs in the overall population
    13. Vital signs, ECG, and laboratory assessments in the overall population
    14. Rate of receipt of rescue therapy (rescue per patient per month) in the overall population
    15. Proportion of patients for whom dose and/or frequency of concurrent ITP therapies have increased at week 12 or later in the overall population
    16. Change from baseline in PRO (Functional Assessment of Chronic Illness Therapy Fatigue Scale [FACIT-Fatigue], Functional Assessment of Cancer Therapy questionnaire-Th6 [Fact-Th6]) and QoL (Short Form-36
    [SF-36]) at planned visits in the overall population
    17. Incidence and prevalence of antibodies to efgartigimod and/or rHuPH20 in the overall population
    18. Titers of antibodies to efgartigimod and/or rHuPH20 in the overall population
    19. Presence of neutralizing antibodies (NAb) against efgartigimod and/or rHuPH20, and titers of NAb against efgartigimod and/or rHuPH20 in the overall population
    20. Serum efgartigimod concentration observed predose (Ctrough) in the overall population
    21. Pharmacodynamics markers: total IgG and antiplatelet antibody levels in the overall population
    1. Grado di controllo della malattia definito come numero cumulativo di settimane, sul periodo pianificato di trattamento di 24 settimane, con conte piastriniche > e =50×10^9/l nella popolazione con ITP cronica
    2. Quota di pazienti nella popolazione complessiva (ITP cronica e persistente) con una risposta duratura in termini di conta piastrinica definita come l’ottenimento di conte piastriniche > e =50×10^9/l in almeno 4 delle 6 visite tra la settimana 19 e la settimana 24
    3. Quota di pazienti nella popolazione complessiva che ottiene conte piastriniche > e =50×10^9/l in almeno 6 delle 8 visite tra la settimana 17 e la settimana 24 della sperimentazione
    4. Quota di pazienti nella popolazione complessiva con una risposta piastrinica complessiva definita come l’ottenimento di una conta piastrinica > e =50×10^9/l in almeno 4 occasioni in qualunque momento nel periodo di trattamento di 24 settimane
    5. Grado di controllo della malattia definito come numero cumulativo di settimane entro la settimana 12 con conte piastriniche > e =50×10^9/l nella popolazione complessiva
    6. Quota di pazienti nella popolazione complessiva con una risposta piastrinica complessiva definita come l’ottenimento di una conta piastrinica > e =50×10^9/l in almeno 4 occasioni in qualunque momento fino alla settimana 12
    7. Variazione media della conta piastrinica rispetto al basale in ciascuna visita nella popolazione complessiva
    8. Tempo alla risposta definito come il tempo all’ottenimento di 2 conte piastriniche consecutive > e =50×10^9/l nella popolazione complessiva
    9. Numero cumulativo di settimane, sul periodo pianificato di trattamento di 24 settimane, con conte piastriniche > e =30×10^9/l e > e =20×10^9/l sopra il livello basale nella popolazione complessiva
    10. Nei pazienti con conta piastrinica al basale <15×10^9/l, il numero cumulativo di settimane, sul periodo pianificato di trattamento di 24 settimane, con conte piastriniche > e =30×10^9/l e > e =20×10^9/l sopra il livello basale nella popolazione complessiva
    11. Incidenza e gravità degli eventi di sanguinamento secondo la classificazione dell’Organizzazione mondiale della sanità (OMS) nella popolazione complessiva
    12. Incidenza e gravità degli EA, degli EA di speciale interesse (EASI) e degli EAS nella popolazione complessiva
    13. Parametri vitali, ECG e valutazioni di laboratorio nella popolazione complessiva
    14. Tasso di assunzione della terapia di salvataggio (salvataggio per paziente per mese) nella popolazione complessiva
    15. Quota di pazienti nei quali a partire dalla settimana 12 la dose e/o la frequenza delle terapie concomitanti per l’ITP sono state incrementate nella popolazione complessiva
    16. Modifica rispetto al basale dei PRO (Functional Assessment of Chronic Illness Therapy Fatigue Scale [Scala di valutazione funzionale della stanchezza nella terapia delle malattie croniche, FACIT-Fatigue], Functional Assessment of Cancer Therapy questionnaire-Th6 [Questionario per la valutazione funzionale della terapia oncologica, Fact-Th6]) e della QdV (Short Form-36 [Modulo breve, SF-36]) alle visite pianificate nella popolazione complessiva
    17. Incidenza e prevalenza degli anticorpi diretti contro efgartigimod e/o rHuPH20 nella popolazione complessiva
    18. Titoli degli anticorpi diretti contro efgartigimod e/o rHuPH20 nella popolazione complessiva
    19. Presenza di anticorpi neutralizzanti (NAb, neutralizing antibody) diretti contro efgartigimod e/o rHuPH20 e titoli di NAb diretti contro efgartigimod e/o rHuPH20 nella popolazione complessiva
    20. Concentrazione sierica di efgartigimod osservata prima della somministrazione (Cvalle) nella popolazione complessiva
    21. Marker farmacodinamici: livelli di IgG totali e anticorpi antipiastrine nella popolazione complessiva
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Up to 24 weeks
    2. Up to 5 weeks (between week 19-24)
    3. Up to 7 weeks (between week 17-24)
    4. Up to 24 weeks
    5. Up to 12 weeks
    6. Up to 12 weeks
    7. Up to 35 weeks
    8. Up to 35 weeks
    9. Up to 24 weeks
    10. Up to 24 weeks
    11. Up to 35 weeks
    12.Up to 35 weeks
    13. Up to 35 weeks
    14. Up to 35 weeks
    15. Up to 23 weeks (between week 12-35)
    16. Up to 24 weeks
    17. Up to 35 weeks
    18. Up to 35 weeks
    19. Up to 35 weeks
    20. Up to 35 weeks
    21. Up to 35 weeks
    1. Fino a 24 settimane
    2. Fino a 5 settimane (tra le settimane 19-24)
    3. Fino a 7 settimane (tra le settimane 17-24)
    4. Fino a 24 settimane
    5. Fino a 12 settimane
    6. Fino a 12 settimane
    7. Fino a 35 settimane
    8. Fino a 35 settimane
    9. Fino a 24 settimane
    10. Fino a 24 settimane
    11. Fino a 35 settimane
    12. Fino a 35 settimane
    13. Fino a 35 settimane
    14. Fino a 35 settimane
    15. Fino a 23 settimane (tra le settimane 12-35)
    16. Fino a 24 settimane
    17. Fino a 35 settimane
    18. Fino a 35 settimane
    19. Fino a 35 settimane
    20. Fino a 35 settimane
    21. Fino a 35 settimane
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    Immunogenicità
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA55
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Chile
    China
    Colombia
    Georgia
    Israel
    Japan
    Jordan
    Korea, Republic of
    Mexico
    New Zealand
    Peru
    Russian Federation
    Serbia
    South Africa
    Taiwan
    Thailand
    Tunisia
    Turkey
    United States
    Bulgaria
    Denmark
    France
    Germany
    Greece
    Ireland
    Italy
    Latvia
    Norway
    Poland
    Portugal
    Romania
    Spain
    United Kingdom
    Argentina
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 136
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state17
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 49
    F.4.2.2In the whole clinical trial 156
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants completing the 24-week randomized trial period will perform the end-of-treatment visit and can enter the open-label extension trial (ARGX-113-2005).
    I partecipanti che completeranno il periodo della sperimentazione randomizzata di 24 settimane si sottoporranno alla visita di fine trattamento e potranno accedere alla sperimentazione di estensione in aperto (ARGX-113-2005).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-06-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-05-13
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA